摘要
针对我国最常见不可逆致盲眼病—原发性闭角型青光眼(以下简称闭青)的高患病率和高致盲率的问题,项目组从发病机制和早期诊断及治疗技术入手,系统地研究了我国闭青患者的房角解剖结构,发现了我国闭青的发病机制,建立了新的机制分类;对亚洲8个国家和地区的闭青患者和正常人群进行了分子遗传学研究,首次发现与闭青发生相关的4个相关基因;研发了闭青筛查的关键设备和筛查技术;揭示了急性闭角型青光眼损伤的新分子机制,创立了急性闭角型青光眼的干预流程;首先提出闭青循序性治疗模式,改良了手术技术,构建适合中国人的慢性闭角型青光眼处理流程,提高了治疗效果。由此,全面提升了闭青的科学认知水平和临床诊治水平,本项目完成了我国闭青防治技术从技术跟踪到技术引领的跨越。
Primary angle closure glaucoma(PACG) is the most prevalent and irreversible blindness disease in China and Asia and the blindness rate is as high as 37.5% -75.0%. We systemically investigated the structure of the anterior chamber angle and for the first time found the mechanism of angle closure of PACG. Then we established the new PACG classification system. We also launched a genetic research in Asia with 8 countries and areas and found 4 susceptibility genes which were related with the anatomical structure of the anterior chamber angle. We designed and developed the first panoramic ultrasound biomicroscopy (UBM) and early screening method and intervention technology. We found the new molecular mechanism of acute PACG and designed treatment route of acute PACG. We established a step by step treatment mode with drug, laser and surgery of PACG and improved the surgery technique. In a word, the serial study promoted recognition,diagnosis, and treatment of PACG. By the item we completed our nation' s PACG prevention and treatment made a leap from following others to leading the area.
出处
《首都医科大学学报》
CAS
2014年第1期6-9,共4页
Journal of Capital Medical University
关键词
原发性闭角型青光眼
发病机制
筛查
诊断
治疗
primary angle closure glaucoma
mechanism
screening
diagnosis
treatment